ULTRAGENYX - Key Persons

Job Titles:

• Biopharmaceuticals Research and Development Executive
• Chairman of Research and Development Committee
• Chief Patient Officer, Biohaven Pharmaceuticals
• Independent Board Director and Advisor

Dr. Ray is an independent board director and advisor to life sciences companies. Previously, Dr. Ray served as Chief Patient Officer at Biohaven Pharmaceuticals, a public biopharmaceutical company, from March 2022 to December 2022. Prior to his role at Biohaven, he served as Senior Adviser to Bain Capital Life Sciences, an investment company, from February 2021 to March 2022. Prior to Bain Capital, Dr. Ray served as Global President, Head of R&D and Medical, for Pfizer Essential Health and subsequently the Pfizer Upjohn division at Pfizer, Inc., a public pharmaceutical company, from 2017 to January 2021. Prior to Pfizer, he held positions of increasing responsibility at Johnson & Johnson, a public pharmaceutical company, including serving as Senior Vice President, External Affairs (Science and Medicine) in 2017, Senior Vice President, Chief Medical Officer of Janssen from 2012 to 2017 and Senior Vice President, Chief Safety Officer from 2009 to 2012. Dr. Ray is on the Board at Fortrea, a publicly traded, global clinical research organization, and at multiple privately owned life sciences companies. Dr. Ray currently serves as a Trustee at the board of the Hastings Center for bioethics, and as a Visiting Professor of Practice, Faculty of Medical Sciences at Newcastle University in the United Kingdom. Dr. Ray holds a B.S., with Honours, in Immunology and a M.D. (M.B., Ch.B.) from the University of Edinburgh. He also holds an M.B.A. from the Tuck School of Business at Dartmouth College. Amrit Ray, M.D., M.B.A. joined the Ultragenyx Board in April 2022. He currently serves as Chief Patient Officer for Biohaven Pharmaceuticals, a commercial-stage biopharmaceutical company focused on neurological and neuropsychiatric diseases. Prior to joining Biohaven, he was a Senior Advisor to Bain Capital Life Sciences, which invests in biopharmaceutical, medical device, diagnostics, and technology companies. Previously, Dr. Ray served as Global President, Head of R&D and Medical, and Executive Leadership Team member at Pfizer Upjohn where he oversaw all aspects of research, Phases I-IV development, regulatory, safety and medical affairs worldwide. Dr. Ray chaired the R&D Investment Committee and served as the company's most senior decision-maker and spokesperson on patient matters. Before Pfizer, Dr. Ray was Chief Medical Officer and R&D Leadership Team Member for pharmaceuticals at Johnson & Johnson. Dr. Ray earned degrees in Immunology and in Medicine at Edinburgh University, and an MBA at Dartmouth College's Tuck School. He is a Visiting Professor of Practice at the Faculty of Medical Sciences, Newcastle University, UK, and a board member at the EveryLife Foundation for rare diseases.

Job Titles:

• Member of the Board of Directors
• Biotechnology Executive
• Member of Audit / Member of Research and Development
• Member of the Research and Development / Member of the Audit
• Member of the Ultragenyx Board

Dr. Sanders has served as a member of the Ultragenyx board since June 2021. Most recently, she served as executive vice president of development operations at Juno Therapeutics and strategic advisor to the office of the Celgene chief medical officer, following Celgene's acquisition of Juno. She also served as transition advisor to the clinical development team at Bristol Myers Squibb (BMS), which acquired Celgene. Prior to her role at BMS, Dr. Sanders held numerous leadership positions over the course of 23 years at Genentech/Roche, including serving as senior vice president, global head of clinical operations and industry collaboration for six years. Dr. Sanders currently serves as a member of the board of directors of several biotechnology companies including Beigene Ltd., Molecular Templates Inc., Legend Biotech Corporation and AltruBio Inc. (formerly AbGenomics Inc.). Dr. Sanders is an advisory committee member for the George Schultz Innovation Fund of the University of Chicago. She is also co-chair of the board of advisors and chair of the science and technology advisory committee for the Fred Hutchinson Cancer Research Center. Dr. Sanders graduated magna cum laude from the University of the Philippines where she earned a B.S. and M.S. in statistics. She also earned an M.A. and Ph.D. in statistics from the Wharton Doctoral Program at the University of Pennsylvania.

Job Titles:

• Chairman
• Chairman of the Board
• Chairman / Executive Partner, Sofinnova Ventures
• Executive Partner at Sofinnova Ventures
• Member of the Ultragenyx Board

Mr. Welch has served as a member of the Ultragenyx board since April 2015. Mr. Welch serves as the chairperson of public companies Structure Therapeutics (previously known as ShouTi) and Nuvation Bio Inc. He served as chairperson of Avexis Inc prior to its acquisition by Novartis. Prior to these roles he served as an executive partner at Sofinnova Ventures from January 2015 through January 2018. From September 2003 until its acquisition by Roche Holdings in September 2014, Mr. Welch served as CEO and president of biotechnology company InterMune, Inc. Mr. Welch also served as chairperson of InterMune from May 2008 to September 2014. From August 2002 to January 2003, Mr. Welch served as chairperson and CEO of Triangle Pharmaceuticals, Inc. From October 2000 to June 2002, Mr. Welch served as president of the pharmaceutical division of Elan Corporation, PLC. He holds a B.A. from the University of Miami and an M.B.A. from the University of North Carolina. Mr. Welch is currently an Executive Partner at Sofinnova Ventures. Prior to Sofinnova, Mr. Welch served as Chairman, Chief Executive Officer and President of InterMune from May 2008 to October 2014 and served as President and Chief Executive Officer of the Company and a member of the Board from September 2003 to May 2008. From August 2002 to January 2003, Mr. Welch served as Chairman and Chief Executive Officer of Triangle Pharmaceuticals, Inc. From October 2000 to June 2002, Mr. Welch served as president of the pharmaceutical division of Elan Corporation, PLC. Mr. Welch currently serves on the boards of directors of Seattle Genetics and Hyperion Therapeutics. Mr. Welch holds a B.S. from the University of Miami and an M.B.A. from the University of North Carolina.

Job Titles:

• Chairman of Research and Development
• Member of the Ultragenyx Board
• Physician and Biotechnology Executive
• President and Chief Executive Officer, Xtuit, Inc

Dr. Dunsire has served as a member of the Ultragenyx board since April 2017. She served as president and chief executive officer of H. Lundbeck A/S from September 2018 until August 2023. She previously served as president and CEO and a director of Xtuit Pharmaceuticals, Inc., a private biopharmaceutical company, from January 2017 to March 2018. Prior to her position at Xtuit, she served as president and CEO and a director of FORUM Pharmaceuticals Inc., a private pharmaceutical company, from July 2013 to May 2016. Prior to FORUM, Dr. Dunsire worked for Takeda Pharmaceutical Company Limited as a corporate officer from June 2010 to June 2011 and a director from June 2011 to June 2013. She served as president, CEO and a director of Millennium Pharmaceuticals, Inc. between 2005 and 2008, when it was acquired by Takeda, and then as president and CEO of Millennium: The Takeda Oncology Company after the acquisition between 2008 and 2013. Prior to Millennium, Dr. Dunsire held various roles of increasing responsibility at Novartis Pharma AG between 1988 and 2005. She currently serves as a director of Syros Pharmaceuticals. Dr. Dunsire obtained an MBBCh from the University of the Witwatersrand.

Job Titles:

• Chief Technical Operations Officer and Executive Vice President, Gene Therapy Research and Development

Mr. Huang joined Ultragenyx in May 2015 and is responsible for leading the technical and pharmaceutical development, manufacturing and supply chain functions, in addition to the company's gene therapy platform strategy, research and product development functions. Prior to joining Ultragenyx, Mr. Huang was senior vice president at InterMune Inc., where he led the global manufacturing organization and supply chain activities for the company. Prior to InterMune, he served as vice president of biologics manufacturing and development for Allergan, Inc. Earlier in his career, Mr. Huang held positions at Novartis AG (formerly Chiron, Inc), Genentech, Inc., and Synergen, where he worked in manufacturing, quality and process development. Mr. Huang serves on the board of directors of MassBio and CytoDel and on the technical advisory board of Solid Biosciences. Mr. Huang earned a B.A. in chemistry from Knox College.

Job Titles:

• Chief Executive Officer
• Director
• President

Dr. Kakkis is currently Ultragenyx's President and Chief Executive Officer. He is also President of the non-profit EveryLife Foundation for Rare Diseases, an organization he founded in 2009 to work on regulatory policy issues. Over the last 22 years Dr. Kakkis is best known for his work developing novel treatments for rare disorders. He began his work developing an enzyme replacement therapy (Aldurazyme®) for the rare disorder MPS I, with minimal funding and support. The struggle to get the therapy translated from a successful canine model to patients succeeded due to the critical financial support of the Ryan Foundation, a patient organization formed by Mark and Jeanne Dant for their son Ryan. Aldurazyme development was later supported by BioMarin and Genzyme leading to FDA approval in 2003. After joining BioMarin in 1998, Dr. Kakkis guided the development and approval of two more treatments for rare disorders, MPS VI and PKU, and has contributed to the initiation of 7 other treatment programs for rare disorders, three of which are now in clinical development or approved. After 11 years at BioMarin, Dr. Kakkis funded and launched the EveryLife Foundation for Rare Diseases, a non-profit foundation dedicated to the acceleration of biotech innovation for rare diseases through practical and scientifically sound improvements to development strategies, regulatory policy and law. The Foundation successfully advocated for improvements to the accelerated approval pathway for rare disease treatments that was passed by Congress in FDASIA in 2012. Dr. Kakkis went on to found Ultragenyx in 2010 to focus on developing as many rare and ultra-rare disease therapeutics as possible. Since its founding, Ultragenyx has grown to more than 100 employees developing treatments for five rare and ultra-rare diseases in Phase 2 and Phase 3 clinical development. The company went public in January 2014 (RARE NASDAQ). Dr. Kakkis is board certified in both Pediatrics and Medical Genetics. He graduated from Pomona College, magna cum laude and received the Vaile prize for his research. He received combined M.D. and Ph.D. degrees from the UCLA Medical Scientist Program and received the Bogen prize for his research. He completed a Pediatrics residency and Medical Genetics Training Fellowship at Harbor- UCLA Medical Center from 1989-1993 and from 1993 to 1998, was an assistant professor of Pediatrics at Harbor-UCLA Medical Center where he initiated the enzyme therapy program for MPS I.

Job Titles:

• Chief Medical Officer
• Executive Vice President

Dr. Crombez joined Ultragenyx following the acquisition of Dimension Therapeutics in November 2017. As Chief Medical Officer and Executive Vice President, Dr. Crombez is responsible for strategic leadership of the clinical development and translational research programs, and oversees global development functions including Clinical Development, Clinical Operations, BioMetrics, Endpoint Development and Strategy, Regulatory Affairs and Drug Safety/Pharmacovigilance. Previously, Dr. Crombez served as Ultragenyx's Chief Medical Officer for gene therapy and inborn errors of metabolism, overseeing global clinical development and execution for the company's gene therapy programs. At Dimension Therapeutics, Dr. Crombez served as Chief Medical Officer and led the clinical development efforts for clinical gene therapy programs in hemophilia B, hemophilia A, ornithine transcarbamylase (OTC) deficiency and glycogen storage disease type Ia (GSDIa). Previously, he worked at Shire in its Human Genetics Therapy business unit. Dr. Crombez is an appointed industry representative on the FDA Cellular, Tissue and Gene Therapies Advisory Committee. Before joining industry, he was assistant professor, Department of Pediatrics, Division of Medical Genetics at the David Geffen School of Medicine at the University of California, Los Angeles (UCLA). Dr. Crombez is a board-certified clinical geneticist and completed residencies in pediatrics and medical genetics and a fellowship in clinical biochemical genetics at the UCLA School of Medicine. Dr. Crombez obtained his B.S. degree in biology from the University of Michigan, Ann Arbor, and his M.D. degree from Wayne State University School of Medicine, Detroit.

Job Titles:

• Chief Commercial Officer
• Executive Vice President
• in 2017 As Senior Vice President, Head of North American Commercial Operations

Mr. Harris joined Ultragenyx in 2017 as Senior Vice President, Head of North American Commercial Operations, and was promoted to Chief Commercial Officer in June 2019. In his current role, he is responsible for all worldwide commercial operations. Prior to joining Ultragenyx in 2017, Mr. Harris spent six years at Crescendo Bioscience, a subsidiary of Myriad Genetics, Inc. At Crescendo he held various leadership positions, most recently as Vice President of Commercial, leading all aspects of marketing, sales, managed care and customer service. Mr. Harris previously served as Vice President of Pulmonology Marketing at Intermune, Inc. Earlier in his career he held positions in the commercial organizations at Elan Pharmaceuticals, Inc., Genentech, Inc., and Bristol Myers Squibb Company. In addition to the Crysvita®, Mepsevii®, and Dojolvi® launches, Mr. Harris has been involved in the launches of Tarceva®, Tysabri® and Vectra-DA®. To begin his professional career, Mr. Harris served as a Lieutenant Commander in Naval Aviation and Congressional Fellow for the United States Navy. Mr. Harris serves on the Board of Directors of Denali Therapeutics. Mr. Harris received his Masters of Business Administration at the Wharton School of Business, and Bachelor of Science at the United States Naval Academy.

Job Titles:

• Chief Human Resources Officer
• Executive Vice President

Mr. Meyer joined Ultragenyx in September 2020 and is responsible for leading the company's global human resources and facilities operations with direct responsibility for driving the corporation's global capabilities in talent management, culture, total rewards, organizational effectiveness, IT and facilities management. He joined Ultragenyx from Portola Pharmaceuticals (acquired by Alexion) where he spent two years as Executive Vice President and Chief Human Resources Officer. Before Portola, he spent more than 13 years at Celgene, most recently as Executive Vice President of Human Resources and Corporate Services. Prior to Celgene, Mr. Meyer spent 10 years at Motorola in a variety of human resource roles. Mr. Meyer holds a B.S. in business management with a concentration in management information systems from Widener University.

Job Titles:

• Chief Financial Officer and Executive Vice President, Corporate Strategy

Mr. Horn joined Ultragenyx in October 2023 and is responsible for leading the company's global finance, accounting, corporate strategy and investor relations functions. He joined Ultragenyx from Vir Biotechnology, where he served as CFO and as a member of Vir's founding management team, guiding the rapid transformation of Vir to a public, commercial-stage organization. Prior to Vir, Mr. Horn was at Biogen where he served first as vice president, strategic corporate finance and then as vice president, business planning. Previously, he held positions of increasing responsibility as a consultant in the Pharmaceutical and Medical Products Practice at McKinsey & Company, and as an equity research analyst in the Life Sciences group at UBS Group AG. Mr. Horn received his B.A. in Economics from Princeton University and his M.B.A. from the Wharton School of the University of Pennsylvania.

Job Titles:

• Chief Quality Operations Officer and Executive Vice President, Translational Sciences

Mr. Pinion joined Ultragenyx in July 2015 as CQOO and EVP, where he provides leadership for the company's translational sciences functions, including Pharmacology and Toxicology, Research and Bioanalytical Development, as well as GxP Quality and Compliance, Validation and CMC Analytical Development and QC. Prior to joining Ultragenyx, Mr. Pinion spent 10 years at Genentech (subsequently Roche), most recently as Senior Vice President and Global Head of Quality and Compliance for Pharma Technical Operations based in Basel, Switzerland. Before Genentech, Mr. Pinion spent 17 years in operational and senior leadership roles in Baxter International's Renal, Bioscience, Parenterals and Device divisions. Mr. Pinion serves on the Board of Directors and as Chair of the Audit and Risk Committee of Aroa Biosurgery Ltd. He received a B.S. in mechanical engineering from West Virginia University.

Job Titles:

• Chairman of the Audit Committee
• Member of the Board
• Biotechnology Executive
• Chairman of Audit / Member of Nominating and Corporate Governance
• Director / Former Executive Vice President and Chief Financial Officer, Onyx Pharmaceuticals, Inc
• Member of the Ultragenyx Board

Mr. Fust has served as a member of the Ultragenyx board since January 2014. Currently, he is a board member and an advisor to life sciences companies. Mr. Fust served as executive vice president and chief financial officer of Onyx Pharmaceuticals, Inc. from January 2009 until January 2014, when he retired. From May 2003 to December 2008, Mr. Fust served as CFO of Jazz Pharmaceuticals, Inc. From 2002 to 2003, Mr. Fust served as CFO at Perlegen Sciences. Previously, he was senior vice president and CFO at ALZA Corporation, where he was an executive from 1996 until 2002. From 1991 until 1996, Mr. Fust was a manager in the healthcare strategy practice at Andersen Consulting. Mr. Fust serves on the board of directors of Atara Biotherapeutics, Inc., Crinetics Pharmaceuticals, Inc., ArsenalBio and Neumora. He is on the Inclusive Governance Advisory Council of the National Association of Corporate Directors and serves as senior advisor to Out Leadership. Mr. Fust received a B.A. from the University of Minnesota and an M.B.A. from the Stanford Graduate School of Business.

Job Titles:

• Chairman of the Compensation Committee
• Chief Executive Officer
• Member of the Board
• President
• Director / President and Chief Executive Officer, Orexigen Therapeutics, Inc
• Member of Audit

Mr. Narachi joined Ultragenyx as a board member in February 2015. Mr. Narachi currently serves as President and Chief Executive Officer and a director of Orexigen Therapeutics, Inc., a position he has held since March 2009. Previously, Mr. Narachi served as Chairman, Chief Executive Officer and President of Ren Pharmaceuticals, Inc., a private biotechnology company, from November 2006 to March 2009. From August 2002 to January 2008, Mr. Narachi served as chairman of the board of directors of Naryx Pharma, Inc., a private pharmaceutical company. Mr. Narachi joined Amgen in 1984 and held various senior positions throughout the organization over a 20 year career including: Vice President of Development and Representative Director for Amgen Japan; Head of Corporate Strategic Planning; Chief Operations Officer of Amgen BioPharma; and Vice President, Licensing and Business Development. He served as General Manager of Amgen's Anemia Business from 1999 to 2003 until his retirement in 2004 as an officer and Vice President of Amgen, Inc. He currently serves as the chairman of the board of directors of Celladon Corporation, a publicly traded biotechnology company. Mr. Narachi received a B.S. in Biology and an M.A. degree in Biology and Genetics from the University of California at Davis. He received an M.B.A. from the Anderson Graduate School of Management at University of California, Los Angeles.

Job Titles:

• Chairman of the Nominating and Corporate Governance Committee
• Director
• Chairman of Nominating and Corporate Governance / Member of Research and Development
• Chief Executive Officer of ReCode Therapeutics
• Member of Our Board
• Member of the Ultragenyx Board

Dr. Suliman has served as a member of the Ultragenyx board since February 2019. Dr. Suliman currently serves as chief executive officer of ReCode Therapeutics, a privately-held genetic medicines company. Previously Dr. Suliman was president and COO of Alector, an immuno-neurology company focused on neurodegenerative diseases. Dr. Suliman has held executive management and leadership roles at Theravance Biopharma, Inc., Genentech, Inc., Roche and Gilead Sciences, Inc. in business development, R&D portfolio management and operations and strategy in the past decade. Prior to Gilead, Dr. Suliman was an investment banker advising public and private companies on buy- and sell-side transactions. Dr. Suliman received her M.D. (MB, ChB) at the University of Cape Town Medical School, South Africa, and holds an M.B.A., with distinction and M.Phil. in Development Studies degrees from Oxford University, where she was a Rhodes Scholar. Dr. Suliman serves as the chair of Executive Women in Bio and serves on the board of directors for life science technology company 10x Genomics (NASDAQ: TXG). Dr. Suliman has served as a member of our Board since January 2019. Dr. Suliman was previously Senior Vice President, Corporate Development and Strategy of Theravance Biopharma, Inc., a position she held since July 2017. Prior to her position at Theravance, Dr. Suliman worked for Genentech, Inc. as Group Leader and Project Team Leader in the R&D Portfolio Management and Operations Group from September 2010 to May 2015 and then as Vice President and Global Therapeutic Head, Roche Partnering from June 2015 to July 2017. Prior to Genentech, Dr. Suliman held various management roles of increasing responsibility at Gilead Sciences, Inc. between January 2005 and September 2010. Prior to Gilead, Dr. Suliman was an investment banker with Lehman Brothers and Petkevich & Partners, advising public and private companies on buy- and sell-side transactions. She is a member of the board of directors of Parvus Therapeutics, Inc., a private biopharmaceutical company. Dr. Suliman received her M.D. at the University of Cape Town Medical School, South Africa, and holds an M.B.A, with distinction, and M.Phil. in Development Studies degrees from Oxford University, where she was a Rhodes Scholar.